Racial discrimination among women seeking breast cancer care.

IF 6.5 2区医学 Q1 ONCOLOGY NPJ Breast Cancer Pub Date : 2025-01-16 DOI:10.1038/s41523-025-00717-y

Lauren J Oshry, Ruth I Lederman, Haley Gagnon, Tsion Fikre, Daniel A Gundersen, Anna C Revette, Ashley Odai-Afotey, Olga Kantor, Dawn L Hershman, Katherine D Crew, Nancy L Keating, Rachel A Freedman, Naomi Y Ko

{"title":"Racial discrimination among women seeking breast cancer care.","authors":"Lauren J Oshry, Ruth I Lederman, Haley Gagnon, Tsion Fikre, Daniel A Gundersen, Anna C Revette, Ashley Odai-Afotey, Olga Kantor, Dawn L Hershman, Katherine D Crew, Nancy L Keating, Rachel A Freedman, Naomi Y Ko","doi":"10.1038/s41523-025-00717-y","DOIUrl":null,"url":null,"abstract":"<p><p>Discrimination can contribute to worse health outcomes, but its prevalence in breast cancer is not well studied. We aimed to understand how women with stage I-III breast cancer faced discrimination in health care and everyday settings through the Everyday Discrimination Scale, cross-sectional survey. 296 women, 178 (60%) Non-Hispanic White (NHW), 76 (26%) Non-Hispanic Black (NHB), and 42 (14%) Hispanic participated. NHB women reported significantly more discrimination in everyday life compared to NHW women (score 20.1 vs 16.1, p < 0.001) and Hispanic women (score 20.1 vs 16.0, p < 0.001). In the health care setting, NHB had statistically more frequent reports of being ignored (23.7% vs. 5.6%), treated with less respect (21.1% vs. 7.3%), and treated with less courtesy (18.7% vs. 6.2%; all P = < 0.001) when compared to NHW women. NHB women experience a higher degree of discrimination both inside and outside of health care. Further research to understand discrimination on breast cancer outcomes is warranted.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"4"},"PeriodicalIF":6.5000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739410/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41523-025-00717-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Discrimination can contribute to worse health outcomes, but its prevalence in breast cancer is not well studied. We aimed to understand how women with stage I-III breast cancer faced discrimination in health care and everyday settings through the Everyday Discrimination Scale, cross-sectional survey. 296 women, 178 (60%) Non-Hispanic White (NHW), 76 (26%) Non-Hispanic Black (NHB), and 42 (14%) Hispanic participated. NHB women reported significantly more discrimination in everyday life compared to NHW women (score 20.1 vs 16.1, p < 0.001) and Hispanic women (score 20.1 vs 16.0, p < 0.001). In the health care setting, NHB had statistically more frequent reports of being ignored (23.7% vs. 5.6%), treated with less respect (21.1% vs. 7.3%), and treated with less courtesy (18.7% vs. 6.2%; all P = < 0.001) when compared to NHW women. NHB women experience a higher degree of discrimination both inside and outside of health care. Further research to understand discrimination on breast cancer outcomes is warranted.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

寻求乳腺癌治疗的妇女受到种族歧视。

歧视可能导致更糟糕的健康结果，但其在乳腺癌中的普遍程度尚未得到充分研究。我们旨在通过日常歧视量表和横断面调查了解I-III期乳腺癌妇女如何在医疗保健和日常环境中面临歧视。296名女性，178名（60%）非西班牙裔白人（NHW）， 76名（26%）非西班牙裔黑人（NHB）和42名（14%）西班牙裔参与。NHB组妇女在日常生活中受到的歧视明显多于NHW组妇女(得分20.1比16.1,p

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

NPJ Breast Cancer Medicine-Pharmacology (medical)

CiteScore

10.10

自引率

1.70%

发文量

122

审稿时长

9 weeks

期刊介绍： npj Breast Cancer publishes original research articles, reviews, brief correspondence, meeting reports, editorial summaries and hypothesis generating observations which could be unexplained or preliminary findings from experiments, novel ideas, or the framing of new questions that need to be solved. Featured topics of the journal include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies largely targeting signal transduction pathways, carcinogenesis including hereditary susceptibility and molecular epidemiology, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and their perturbation, and studies of the tumor microenvironment.